DURHAM, N.C.--(BUSINESS WIRE)--Xilis, Inc., a pioneering company using its MicroOrganoSphere (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and ...

DURHAM, N.C.--(BUSINESS WIRE)--Xilis, Inc., a pioneering company developing its MicroOrganoSphere TM (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and ...

DURHAM, N.C.--(BUSINESS WIRE)--Xilis, Inc., a pioneering company developing its MicroOrganoSphere™ (MOS™) technology to guide precision therapy for cancer patients and accelerate drug discovery and ...

Company developing breakthrough clinically-predictive patient tumor avatar platform with native tumor–immune biology to accelerate drug discovery and development and DURHAM, N.C. – December 15, 2022 – ...

From the moment cancer is diagnosed, the clock is ticking. Early treatment can lead to better outcomes, but physicians must first choose a drug. It can take months to assess how the selected drug is ...

Though the central premise of cancer treatment is to eliminate any and all evidence of a tumor, Xilis’ approach begins by creating thousands of more replicas of a patient’s cancer cells to inform the ...

DURHAM – Xilis, a startup founded by two professors at Duke University focusing on technology to boost precision health and oncology, has landed $70 million in new funding with Google Ventures among ...

Despite near-miraculous advances in the treatment of cancer in the U.S. and around the world, the disease remains the second leading cause of death in America. The problem is that every manifestation ...

Xilis, a biotech startup founded by Duke University professors, has raised $70 million from investors to fund the development of its experimental cancer treatment technology. The company, founded in ...

xilis , a pioneering biotech company advancing its proprietary MicroOrganoSphereTM (MOS) Platform to accelerate drug discovery and development and advance functional precision medicine for cancer ...